A Phase 2/3 interventional study of Non-invasive transcranial Temporal Interference Stimulation (iTBS-tTIS Striatum) and Concurrent Intensive Motor Rehabilitation in Stroke and Stroke Assessment, sponsored by Friedhelm Hummel. Not yet recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-28.
Sponsored by Friedhelm Hummel · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 216 studies in Stroke with a site in Switzerland — 46 open to participants now, 60 under way, 6 of them phase 3. Stroke · Switzerland.
Among the 216 studies in Stroke with a site in Switzerland, this one is the 70th largest by planned enrollment of the 147 interventional ones that give a count, is one of 12 that started in 2026, is one of 3 in phase 2/3, reaches primary completion later than 51 of the 59 other live ones, and was the 215th registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →46 of the 216 studies in Stroke with a site in Switzerland are open now. Recruiting first, the newest first:
Hospital Universitari Vall d'Hebron Research Institute · Sites in Switzerland, Belgium, Germany and 3 more countries
Ages 18+
Ecole Polytechnique Fédérale de Lausanne · Sites in Switzerland
Ages 18–70
Centre Hospitalier Universitaire Vaudois · Sites in Switzerland
Ages 18–85
School of Health Sciences Geneva · Sites in Switzerland
Ages 18+
Sigmund Freud PrivatUniversitat · Sites in Switzerland, Austria, Germany
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
216 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 37 · Phase 4 7
First in 1998; this study’s year is marked. 12 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 84 is above the median of 48 across 6,049 interventional studies indexed under Stroke.
Median enrollment 79 across the 147 interventional studies, 200 across the 69 observational. Of the 134 that completed or were terminated, 19 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 216 have an industry lead sponsor. The 10 most frequent:
Friedhelm Hummel is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Friedhelm Hummel has 2 studies filed under Stroke — fewer than ten, so there is no comparison to draw.
10 of the studies in Stroke with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02756091Insel Gruppe AG, University Hospital BernInternational Intracranial Dissection Study | 2026-11-30 |
| NCT06466772University of ZurichPrecision Sensorimotor Neurorehabilitation Through Personalized Stimulation Loops | 2026-12 |
| NCT07739134ETH ZurichMultimodal Tracking of Therapy Activity and Effort During Rehabilitation | 2026-12-30 |
| NCT07299994Sigmund Freud PrivatUniversitatEfficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease | 2026-12-31 |
| NCT07444151School of Health Sciences GenevaPost-Stroke Fatigue Perception Study (ReFast) | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 216 studies in Stroke with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
NIMBUS is a clinical study evaluating a new, non-invasive brain stimulation treatment to improve arm and hand function in people with long-term effects of stroke. The treatment uses a personalized method to stimulate deeper areas of the brain through the scalp, without surgery, while participants undergo intensive physiotherapy rehabilitation. Physiotherapy in combination with the brain stimulation will occur three times a day over the course of a week. In the study, participants are randomly assigned to receive either the active treatment or a sham (inactive) version, so researchers can compare the outcomes fairly. The study will assess whether the treatment is safe, feasible, and effective by measuring changes in arm movement, daily activities, and brain function before and after the treatment. The goal is to determine whether this approach can enhance recovery after stroke and support the development of improved rehabilitation therapies.
In sum, the striatum is a key structure of motor control and (re-)learning. The striatum contributes to multiple levels including initiation of movements, facilitation of goal-directed actions, habit formation and especially motor skill acquisition, consolidation and retention. This makes the striatum a very promising target for interventional strategies based on striatal neuromodulation combined with motor (re-)learning after brain lesions. This concept is further supported by current evidence that the striatum is a highly neuroplastic area given the striatum's composition and known associations with critical neurotransmitter systems.
In first-in-human proof-of-concept studies, **the investigators demonstrated** that striatal neuromodulation by tTIS is feasible and safe. Applying theta burst patterned tTIS (iTBS-tTIS) to the striatum led to a significant, improvement in motor skill acquisition and increased activity changes in the striatum and the connected network. The behavioral improvement was most pronounced in healthy old adults, typically in comparable age as stroke patients. Additional proof-of-concept studies further support the feasibility and efficacy of tTIS in brain lesioned patient cohorts. For instance, **the investigators conducted** a study involving 15 patients with traumatic brain injury (TBI) and, demonstrating that tTIS significantly improved motor learning and retention, with clinically meaningful effects observed for at least 24 hours after stimulation. Moreover, a study in patients with Parkinson's disease demonstrated that tTIS can improve motor symptoms, particularly bradykinesia and tremor. Collectively, these results highlight that tTIS is a safe and well-tolerated technique, demonstrating strong potential for improving motor outcomes in various neurological conditions. To achieve not only the demonstrated shorter-lasting, but long-lasting effects in the present project, **the investigators will significantly enhance the dosage and apply an accelerated stimulation protocol with three stimulation sessions per day for one week.**
**Secondary research questions.** The core aspect of the present project is to determine the behavioral effects of the suggested transformative interventional strategy on motor recovery. However, **the present project also requires personalized electrode placement and assessment of the impact of the intervention on daily life activities, higher order cognitive functions, brain activity and long-term effects. The project should further allow evaluation of factors that impact the degree of individual treatment response, paving the way to biomarkers.**
**Treatment-induced changes in sensory, psycho-social and cognitive domains.**
Non-motor effects of the therapy will be assessed through changes from before (week 1) to after (week 3) the intervention in: mood and motivation, fatigue and sleep quality, sensory function, attention, executive functions, and spatial awareness. These outcomes provide a concise characterization of therapy-related changes beyond motor performance.
**Treatment-induced changes in network properties (Multi-modal MRI and electrophysiology).**
Neurobiological effects of the therapy will be evaluated through changes in: structural and functional brain connectivity, global network efficiency and integration, cortical excitability and excitation-inhibition balance. These outcomes will support interpretation of clinical effects and mechanisms of recovery.
**Long-lasting treatment-induced changes in behavior:** To determine whether the achieved effects of the proposed interventional strategy persist, **the investigators will invite the patients** for a clinical, behavioral follow-up evaluation (FU) 3 months after the end of the treatment. Outcomes of interest will be similar to the primary outcomes, and to those established to assess changes in daily-life behavior (questionnaires and Smart Kitchen assessment) and in sensory, psycho-social, and cognitive domains.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
for NIBS or MRI
a. Electronic or ferromagnetic medical implants/device, non-MRI compatible metal implant, b. Fully or partially implanted conductive objects i. Passive implants: stents, orthopedic/orthodontic implants, screws, shunts, etc.
ii. Active implants: cochlear implants, deep brain stimulation leads and electrodes, fully implanted brain monitoring devices iii. Partially implanted devices: monitoring electrodes (e.g., stereoelectroencephalography, electrocortigraphy, etc.
iv. Surface-mounted conductive objects: conductive low-impedance structure mounted to the skin that may introduce shortcuts.
c. History of seizures d. Medication that significantly interacts with NIBS being benzodiazepines, tricyclic antidepressants and antipsychotics.
e. Non-intact skin where electrodes are intended ot be placed
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive personalized, non-invasive deep brain stimulation targeting the striatum using transcranial electrical temporal interference stimulation (tTIS) combined with intermittent theta-burst stimulation (iTBS). Stimulation is delivered via individually positioned electrodes based on each participant's brain anatomy, concurrently with intensive upper-limb rehabilitation training (3 sessions per day for 1 week).
Device: Non-invasive transcranial Temporal Interference Stimulation (iTBS-tTIS Striatum) · Behavioral: Concurrent Intensive Motor Rehabilitation
Participants receive sham (inactive) transcranial electrical temporal interference stimulation targeting the striatum, delivered with identical setup and procedures as the active condition but without effective stimulation. This is combined with the same intensive upper-limb rehabilitation training protocol (3 sessions per day for 1 week).
Behavioral: Concurrent Intensive Motor Rehabilitation · Device: Non-invasive transcranial Temporal Interference Stimulation sham-tTIS Striatum)
Transcranial Temporal Interference Stimulation (tTIS) is a non-invasive neuromodulation technique that applies multiple high-frequency electrical currents via scalp electrodes to generate an amplitude-modulated electric field in deep brain regions without surgery. The technique allows targeting of different deep brain structures depending on electrode configuration and current parameters. In this study, stimulation is individualized to target the striatum using subject-specific electrode placement based on anatomical information. The stimulation is delivered in a theta-burst-patterned protocol designed to induce plasticity-related effects. tTIS is applied concurrently with upper-limb rehabilitative training during each session. The intervention is administered over five consecutive days, with three sessions per day within an accelerated protocol.
Participants undergo intensive, task-oriented upper-limb rehabilitation training focused on improving motor function of the affected arm and hand following stroke. Training is delivered in a structured and personalized manner, adapted to the participant's level of impairment and functional capacity. Each session includes approximately 30 minutes of physiotherapy involving repetitive, goal-directed movements and functional tasks targeting upper-limb use. The rehabilitation is provided concurrently with stimulation (active or sham) and follows an accelerated schedule of three sessions per day over five consecutive days.
Sham Transcranial Temporal Interference Stimulation (tTIS) is a non-invasive neuromodulation procedure that applies two identical high-frequency electrical currents via scalp electrodes. Because the currents have the same frequency, no low-frequency amplitude-modulated electric field is generated in deep brain regions. The sham stimulation uses the same individualized electrode placement based on anatomical information and follows the same stimulation schedule and device settings as the active intervention, while not delivering the temporal interference pattern intended to modulate striatal activity. Sham tTIS is applied concurrently with upper-limb rehabilitative training during each session. The intervention is administered over five consecutive days, with three sessions per day within an accelerated protocol.
Change in Upper-Limb Motor Function (Composite Motor Score)
Upper-limb motor performance assessed using a composite motor score including the Fugl-Meyer Assessment Upper Limb, Pinch \& Grip, Box\&Blocks, Nine-Hole Peg Test, and Action Research Arm Test (ARAT). The primary endpoint is defined as the change from baseline to post-intervention.
Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)
Change in Barthel Index Score
Independence in basic activities of daily living will be assessed using the Barthel Index. The instrument evaluates feeding, bathing, grooming, dressing, bowel and bladder control, toilet use, transfers, mobility, and stair use. The total score ranges from 0 to 100, with higher scores indicating greater independence. The outcome will be the change in total score from baseline to post-intervention and follow-up.
Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)
Changes in daily life-oriented behavior - Questionnaires.
Changes in daily functioning and perceived health will be evaluated from before the therapy (week 1) to after the therapy (week 3) using validated clinical questionnaires and observation scales. Outcomes will include: change in independence in activities of daily living, change in upper-limb performance during daily activities, change in patient-reported global health and well-being.
Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)
Change in Modified Rankin Scale Score
Global disability will be assessed using the Modified Rankin Scale. Scores range from 0 to 5 in the study CRF, with 0 indicating no symptoms and 5 indicating severe disability requiring constant nursing care and attention. The outcome will be the change in score from baseline to post-intervention and follow-up.
Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)
Change in Functional Independence Measure Total Score
Functional independence will be assessed using the Functional Independence Measure (FIM), covering self-care, sphincter control, transfers, locomotion, communication, and social cognition. Individual items are rated from 1 (total assistance) to 7 (complete independence), and the total FIM score will be used as the outcome measure. Higher scores indicate greater functional independence. The outcome will be the change in total score from baseline to post-intervention and follow-up.
Time frame: Baseline (Week 1) and post-intervention (Week 3, ±3 days)
Change in Modified Upper Limb Lucerne ICF-Based Multidisciplinary Observation Scale Score
Daily-life upper-limb function will be assessed using the Modified Upper Limb Lucerne ICF-Based Multidisciplinary Observation Scale (LIMOS). The scale evaluates lifting and carrying objects, fine hand use, hand and arm use, washing, and dressing. The summed score ranges from 0 to 20, with higher scores indicating greater independence in upper-limb-related activities. The outcome will be the change in total score from baseline to post-intervention and follow-up.
Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)
Change in PROMIS Global Health Score
Patient-reported global physical, mental, and social health will be assessed using the PROMIS Global Health questionnaire. Scores will be calculated according to the standardized PROMIS scoring procedure, with higher scores indicating better self-reported health. The outcome will be the change in score from baseline to post-intervention and follow-up.
Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)
Change in Hospital Anxiety and Depression Scale - Anxiety Subscale Score
Anxiety symptoms will be assessed using the Anxiety subscale of the Hospital Anxiety and Depression Scale (HADS-A). The subscale consists of 7 items scored from 0 to 3, yielding a total score from 0 to 21. Higher scores indicate greater anxiety symptom severity. The outcome will be the change in HADS-A score from baseline to post-intervention and follow-up.
Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)
Change in Hospital Anxiety and Depression Scale - Depression Subscale Score
Depressive symptoms will be assessed using the Depression subscale of the Hospital Anxiety and Depression Scale (HADS-D). The subscale consists of 7 items scored from 0 to 3, yielding a total score from 0 to 21. Higher scores indicate greater depressive symptom severity. The outcome will be the change in HADS-D score from baseline to post-intervention and follow-up.
Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)
Change in State-Trait Anxiety Inventory - State Anxiety Score
Current anxiety will be assessed using the State subscale of the State-Trait Anxiety Inventory (STAI-S). The STAI-S consists of 20 items assessing anxiety experienced at the time of assessment. The total score ranges from 20 to 80, with higher scores indicating greater state anxiety. The outcome will be the change in total score from baseline to post-intervention and follow-up.
Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)
Change in State-Trait Anxiety Inventory - Trait Anxiety Score
General anxiety tendency will be assessed using the Trait subscale of the State-Trait Anxiety Inventory (STAI-T). The STAI-T consists of 20 items and yields a total score ranging from 20 to 80, with higher scores indicating greater trait anxiety. The outcome will be the change in total score from baseline to post-intervention and follow-up.
Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)
Change in Multidimensional Fatigue Inventory Score
Fatigue will be assessed using the Multidimensional Fatigue Inventory. The questionnaire contains 20 items rated on a 5-point response scale and assesses general fatigue, physical fatigue, reduced activity, reduced motivation, and mental fatigue. Scores will be calculated according to the standardized scoring procedure, with higher scores indicating greater fatigue. The outcome will be the change in fatigue score from baseline to post-intervention and follow-up.
Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)
Change in Pittsburgh Sleep Quality Index Global Score
Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI). The PSQI assesses sleep quality and disturbances during the preceding month and generates a global score ranging from 0 to 21. Higher scores indicate poorer sleep quality. The outcome will be the change in global PSQI score from baseline to post-intervention and follow-up.
Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)
Change in Apathy Evaluation Scale Self-Rated Score
Motivation and apathy will be assessed using the self-rated Apathy Evaluation Scale. The instrument contains 18 items assessing interest, initiative, engagement, and motivation. The total score will be calculated according to the standardized scoring procedure, with higher scores indicating greater apathy. The outcome will be the change in total score from baseline to post-intervention and follow-up.
Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)
Change in Revised Nottingham Sensory Assessment Score
Somatosensory function will be assessed using the Revised Nottingham Sensory Assessment. The assessment evaluates tactile sensation, proprioception, and stereognosis. Sensory responses are scored according to the standardized assessment criteria, with higher scores reflecting better sensory function. The outcome will be the change in sensory performance from baseline to post-intervention and follow-up.
Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)
Change in Sensitive Neglect Test Single-Task Total Omissions
Spatial attention will be assessed using the single-task condition of the Sensitive Neglect Test (SNT). The outcome measure will be the total number of omitted targets. Higher numbers of omissions indicate greater impairment of visuospatial attention. The outcome will be the change in total omissions from baseline to post-intervention and follow-up.
Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)
Change in Sensitive Neglect Test Dual-Task Total Omissions
Spatial attention under dual-task conditions will be assessed using the dual-task condition of the Sensitive Neglect Test (SNT). The outcome measure will be the total number of omitted targets. Higher numbers of omissions indicate greater impairment of visuospatial attention under dual-task conditions. The outcome will be the change in total omissions from baseline to post-intervention and follow-up.
Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)
Change in Long-Line Bisection Error
Visuospatial attention will be assessed using a line-bisection task. Participants bisect two 20-cm horizontal lines, and the deviation from the true midpoint is measured in millimeters. Deviations to the right of the midpoint are recorded as positive values and deviations to the left as negative values. The mean deviation across the two 20-cm lines will be used as the outcome measure. Values closer to zero indicate more accurate spatial midpoint estimation.
Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)
Change in TAP Phasic Alertness Index
Phasic alertness will be assessed using the alertness module of the Test of Attentional Performance (TAP). Median reaction time is measured in conditions with and without an auditory warning signal. The phasic alertness index is calculated as the difference between median reaction time without and with the warning signal, divided by the overall median reaction time. The outcome will be the change in the phasic alertness index from baseline to post-intervention and follow-up.
Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)
Change in Color Trails Test Interference Index
Divided attention and cognitive flexibility will be assessed using the Color Trails Test. Performance time and errors are recorded for Parts 1 and 2, and an interference index is derived from performance across the two parts. The outcome will be the change in the Color Trails Test interference index from baseline to post-intervention and follow-up.
Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)
Change in Stroop Victoria Test Interference Index
Inhibitory control will be assessed using the Stroop Victoria Test. Completion times are recorded for the Color, Word, and Interference cards. The primary Stroop outcome will be the interference index calculated as completion time for the Interference Card divided by completion time for the Color Card. The outcome will be the change in the interference index from baseline to post-intervention and follow-up.
Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)
Change in Five-Point Test Correct Designs
Nonverbal executive functioning and design fluency will be assessed using the Five-Point Test. The outcome measure will be the number of correct unique designs produced within the standardized task period. Higher values indicate greater design fluency. The outcome will be the change in the number of correct designs from baseline to post-intervention and follow-up.
Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)
Change in Phonological Verbal Fluency Score
Phonological verbal fluency will be assessed by asking participants to generate words beginning with a specified letter during a 1-minute period. Repetitions and errors will be excluded. The outcome measure will be the number of correct words generated, with higher values indicating better verbal fluency. The outcome will be the change from baseline to post-intervention and follow-up.
Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)
Change in Digit Span Forward Total Score
Auditory attention and short-term verbal memory will be assessed using the Digit Span Forward condition. The outcome will be the total number of correctly completed sequences according to the study scoring procedure. Higher scores indicate better performance. The outcome will be the change from baseline to post-intervention and follow-up.
Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)
Change in Digit Span Backward Total Score
Verbal working memory will be assessed using the Digit Span Backward condition. The outcome will be the total number of correctly completed sequences according to the study scoring procedure. Higher scores indicate better working-memory performance. The outcome will be the change from baseline to post-intervention and follow-up.
Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)
Change in Digit Span Sequencing Total Score
Working-memory manipulation will be assessed using the Digit Span Sequencing condition. Participants reproduce orally presented digit sequences in ascending numerical order. The outcome will be the total score according to the study scoring procedure, with higher scores indicating better performance. The outcome will be the change from baseline to post-intervention and follow-up.
Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)
Change in Token Test Total Score
Auditory language comprehension will be assessed using the Token Test. Participants execute increasingly complex verbal commands using colored geometric tokens. Responses are scored according to the study scoring procedure, yielding a maximum total score of 36. Higher scores indicate better auditory comprehension. The outcome will be the change in total score from baseline to post-intervention and follow-up.
Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)
Change in Paretic Upper-Limb Movement Speed During the Smart Kitchen Assessment
Upper-limb movement speed during standardized daily-life-like tasks in the Smart Kitchen Assessment will be quantified using instrumented movement recordings. Movement speed will be calculated as the time to complete each subtask and reported in seconds. The outcome will be the change from baseline to post-intervention and follow-up.
Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)
Change in Paretic Upper-Limb Movement Smoothness During the Smart Kitchen Assessment
Movement smoothness of the paretic upper limb during standardized daily-life-like tasks will be quantified using tortuosity of the active wrist in linear movements (such as reaching or placing) and cycle consistency in periodic movements (such as peeling or grating). Both measures are dimensionless. Lower values of Tortuosity and Higher values of cycle consistency indicate smoother movement. The outcome will be the change from baseline to post-intervention and follow-up.
Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)
Change in Movement Efficiency During the Smart Kitchen Assessment
Movement efficiency during standardized Smart Kitchen tasks will be quantified using using the jerk of the upper limb kinematics and reported in m/s\^3. Lower values indicate greater movement efficiency. The outcome will be the change from baseline to post-intervention and follow-up.
Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)
Change in Bimanual Coordination During the Smart Kitchen Assessment
Bimanual coordination during standardized Smart Kitchen tasks will be quantified using using the time needed to perform bimanual tasks and reported in seconds. Lower values indicate better bimanual coordination. The outcome will be the change from baseline to post-intervention and follow-up.
Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)
Change in Static Resting-State Functional Connectivity Measured With fMRI
Static resting-state functional connectivity will be assessed using functional MRI and quantified from the temporal correlation of resting-state BOLD signals between brain regions. Correlation-based connectivity values will be used to characterize functional coupling within and between brain networks. The outcome will assess changes in static functional connectivity from baseline to post-intervention.
Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days)
Change in Dynamic Resting-State Functional Connectivity Measured With fMRI
Dynamic resting-state functional connectivity will be assessed using functional MRI by quantifying temporal variability in functional coupling between brain regions. Dynamic connectivity will be characterized using the variability of time-resolved functional connections, expressed as the standard deviation of connectivity-related time series. The outcome will assess changes in dynamic functional connectivity from baseline to post-intervention.
Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days)
Association Between Structural Connectivity and Treatment Response
Structural brain connectivity will be assessed at baseline and post-intervention using diffusion-weighted MRI and quantified using streamline-based connectivity between brain regions. Structural connectivity measures will characterize the strength or preservation of anatomical connections and will be examined for association with the magnitude of behavioral response to the intervention.
Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days)
Change in Resting-State EEG Functional Connectivity
Resting-state EEG will be recorded under standardized eyes-open and/or eyes-closed conditions. Functional connectivity will be quantified using Debiased Weighted Phase Lag Index (dwPLI) within the oscillatory bands of interest. The outcome will be the change in dwPLI from baseline to post-intervention.
Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days)
Change in Cortical Excitability Measured With TMS-EEG
Cortical excitability will be assessed using TMS combined with EEG. The outcome measure will be TEP amplitude at predefined components, electrodes, and time intervals, reported in mV. The outcome will be the change from baseline to post-intervention.
Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days)
Change in Excitation-Inhibition Balance Measured With TMS-EEG
Cortical excitation-inhibition balance will be assessed using TMS-EEG and quantified using the amplitude of induced TEPs in response to Paired-pulse Short intracortical inhibition (SICI) and intracortical facilitation (ICF). The measure will be reported in mV. The outcome will be the change in waveform from baseline to post-intervention.
Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days)
Incidence of Adverse Events, Serious Adverse Events, Adverse Device Effects, and Device Deficiencies
Safety will be assessed by recording adverse events, serious adverse events, anticipated and unanticipated adverse device effects, and device deficiencies occurring during the intervention period. The number and proportion of participants experiencing each category of event will be reported together with event type and severity.
Time frame: From the first intervention session through completion of the intervention period at the end of Week 2
Plan to share: Undecided — De-identified individual participant data underlying the results reported in this study, including demographic, clinical, behavioral, kinematic, neuroimaging, and electrophysiological data, will be shared. The study protocol, statistical analysis plan, and analytic code will also be made available. Data will become available beginning 6 months after publication of the primary results and will remain available for at least 5 years. Access will be granted to researchers who provide a methodologically sound proposal, for the purpose of achieving the aims outlined in the approved proposal. Data will be shared upon reasonable request to the Sponsor-Investigator, subject to review and approval of the request and the execution of a data sharing agreement, in accordance with applicable data protection regulations.
Start is estimated for Sep 2026; primary completion for Dec 2029, 39 months later.
Of 27 phase 2/3 interventional studies under Stroke, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 77. This study's planned 39 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Friedhelm Hummel